Literature DB >> 15477202

Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.

Caterina Borgna-Pignatti1, Simone Rugolotto, Piero De Stefano, Huaqing Zhao, Maria Domenica Cappellini, Giovanni Carlo Del Vecchio, Maria Antonietta Romeo, Gian Luca Forni, Maria Rita Gamberini, Roberta Ghilardi, Antonio Piga, Avital Cnaan.   

Abstract

BACKGROUND AND OBJECTIVES: Seven Italian centers reported data on survival, causes of death and appearance of complications in patients with thalassemia major. The interactions between gender, birth cohort, complications, and ferritin on survival and complications were analyzed. DESIGN AND METHODS: Survival after the first decade was studied for 977 patients born since 1960 whereas survival since birth and complication appearance was studied for the 720 patients born after 1970. Better survival was demonstrated for patients born in more recent years (p<0.00005) and for females (p=0.0003); 68% of the patients are alive at the age of 35 years. In the entire population 67% of the deaths were due to heart disease.
RESULTS: There was a significant association between birth cohort and complication-free survival (p<0.0005). The prevalence of complications was: heart failure 6.8%, arrhythmia 5.7%, hypogonadism 54.7%, hypothyroidism 10.8%, diabetes 6.4%, HIV infection 1.7%, and thrombosis 1.1%. Lower ferritin levels were associated with a lower probability of heart failure (hazard ratio =3.35, p<0.005) and with prolonged survival (hazard ratio = 2.45, p<0.005), using a cut-off as low as 1,000 ng/mL. INTERPRETATION AND
CONCLUSIONS: Survival and complication-free survival of patients with thalassemia major continue to improve, especially for female patients born shortly before or after the availability of iron chelation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15477202

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  282 in total

1.  Detection of myocardial iron overload by two-dimensional speckle tracking in patients with beta-thalassaemia major: a combined echocardiographic and T2* segmental CMR study.

Authors:  Fausto Pizzino; Antonella Meloni; Anna Terrizzi; Tommaso Casini; Anna Spasiano; Carlo Cosmi; Massimo Allò; Concetta Zito; Scipione Carerj; Giovanni Donato Aquaro; Gianluca Di Bella; Alessia Pepe
Journal:  Int J Cardiovasc Imaging       Date:  2017-08-02       Impact factor: 2.357

Review 2.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

3.  Beta-thalassemia: from genotype to phenotype.

Authors:  Fabrice Danjou; Franco Anni; Renzo Galanello
Journal:  Haematologica       Date:  2011-11       Impact factor: 9.941

4.  Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.

Authors:  Dudley J Pennell; John B Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi-Kong Li; Vip Viprakasit; Mohsen Saleh Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

5.  In search of the optimal iron chelation therapy for patients with thalassemia major.

Authors:  Vasilios Berdoukas; John Wood
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

6.  Serum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan.

Authors:  Haris Riaz; Talha Riaz; Muhammad Ubaid Khan; Sina Aziz; Faizan Ullah; Anis Rehman; Qandeel Zafar; Abdul Nafey Kazi
Journal:  BMC Res Notes       Date:  2011-08-11

7.  Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

Authors:  Louise de Swart; Jan C M Hendriks; Lisa N van der Vorm; Z Ioav Cabantchik; Patricia J Evans; Eldad A Hod; Gary M Brittenham; Yael Furman; Boguslaw Wojczyk; Mirian C H Janssen; John B Porter; Vera E J M Mattijssen; Bart J Biemond; Marius A MacKenzie; Raffaella Origa; Renzo Galanello; Robert C Hider; Dorine W Swinkels
Journal:  Haematologica       Date:  2015-09-18       Impact factor: 9.941

8.  Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort.

Authors:  Janet L Kwiatkowski; Hae-Young Kim; Alexis A Thompson; Charles T Quinn; Brigitta U Mueller; Isaac Odame; Patricia J Giardina; Elliott P Vichinsky; Jeanne M Boudreaux; Alan R Cohen; John B Porter; Thomas Coates; Nancy F Olivieri; Ellis J Neufeld
Journal:  Blood       Date:  2012-01-25       Impact factor: 22.113

9.  Therapeutic effects of induced pluripotent stem cells in chimeric mice with β-thalassemia.

Authors:  Guanheng Yang; Wansheng Shi; Xingyin Hu; Jingzhi Zhang; Zhijuan Gong; Xinbing Guo; Zhaorui Ren; Fanyi Zeng
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

Review 10.  Estimating tissue iron burden: current status and future prospects.

Authors:  John C Wood
Journal:  Br J Haematol       Date:  2015-03-12       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.